-
TFome could revolutionize cell therapy by delivering off-the-shelf iPSC-based medicines at a pace up to 100X more rapidly than conventional methods via a single-step process with improved potency, efficiency, quality and cost
-
TFome™ is the world’s first “plug-and-play” iPSC cellular programming platform.
-
The company raised $75M from Cormorant Asset Management, Mubadala Capital, a16z Bio + Health, Medical Excellence Capital, Cercano Management, & Pear VC
Poseida Therapeutics Receives RMAT for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month
RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process
FUJIFILM Cellular Dynamics Introduces Human iPSC-derived Sensory Neurons to Advance Pain Research
MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular Dynamics will present iCell Sensory Neurons and other key products in its market-leading neuroscience portfolio at the Society for Neuroscience annual conference in Chicago from October 5-9, 2024 and the Annual Pain Therapeutics Summit in Boston from October 28-29, 2024. [Read more…]
Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates
New assays based on iPSC help accelerate drug discovery by giving drug innovators in neurodegenerative diseases high quality data on a broad range of disease-relevant read-outs.
September 10, 2024, LEIDEN, Netherlands — Ncardia, a leading human iPSC company, announced today the launch of a new panel of ready-to-use assays designed to streamline the screening and selection of new therapeutic candidates, with a specific focus on neurodegenerative diseases. [Read more…]
BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
Cambridge, MA USA, Sept. 03, 2024 — BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. [Read more…]
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 116
- Next Page »